Table 2.

Discrimination and reclassification statistics for the calculated values of the various risk scores that were studied, in both populations of post-MI subjects and for IMACE and DAPT-S in a secondary validation of non-MI poststent subjects

Sex	Model	Derivation c-statistics	Validation c-statistics	NRI index for IMACE vs the indicated score
Female		n=1342	n=576
	IMACE	0.675	0.734	–
	e-IMACE	0.717	0.717	N/C
	IMRS	0.652	0.690	0.478 (P<0.001)
	GRACE	0.603	0.632	0.282 (P<0.001)
	DAPT-S	0.546	0.574	N/C
	DAPT-S no age	0.606	0.649	0.205 (P<0.001)
Male		n=3047	n=1290
	IMACE	0.715	0.672	–
	e-IMACE	0.734	0.667	N/C
	IMRS	0.633	0.629	0.250 (P<0.001)
	GRACE	0.649	0.670	0.127 (P<0.001)
	DAPT-S	0.581	0.551	N/C
	DAPT-S, no age	0.661	0.628	0.157 (P<0.001)
Second validation population of non-MI poststent subjects (women, n=1779; men, n=4977)
Female	IMACE	NA	0.635	–
	DAPT-S	NA	0.510	N/C
	DAPT-S, no age	NA	0.581	0.044 (P<0.001)
Male	IMACE	NA	0.635	–
	DAPT-S	NA	0.553	N/C
	DAPT-S, no age	NA	0.619	0.026 (P<0.001)

NRI index was calculated for validation subjects.

DAPT, dual antiplatelet therapy; DAPT-S, DAPT Study; e-IMACE, enhanced IMACE; GRACE, Global Registry of Acute Coronary Events; IMACE, Intermountain Major Adverse Cardiovascular Events; IMRS, Intermountain Mortality Risk Scores; MI, myocardial infarction; NA, not applicable; N/C, not calculated; NRI, net reclassification improvement.